[250 Pages Report] The global feline atopic dermatitis treatment market is slated to expand at a positive 4.5% CAGR during the assessment period (2022-2032). Sales in the feline atopic dermatitis treatment market are expected to reach US$ 5 Bn by the end of 2022. Growth in the market is primarily attributed to the rising adoption of cats as a companion pet across the globe.
| Report Attribute | Details |
|---|---|
| Feline Atopic Dermatitis Treatment Market Estimated Growth Rate (2022-2032) | 4.5% CAGR |
| Feline Atopic Dermatitis Treatment Market Estimated Size (2022) | US$ 5 billion |
| Feline Atopic Dermatitis Treatment Market Projected Size (2032) | US$ 7 billion |
Atopic dermatitis is the inflammation of skin witnessed in cats and is caused by causative allergens, which are either inhaled or caused by skin contact. With rising adoption of cats as pet, the prevalence of feline atopic dermatitis is surging across the globe.
According to Canadian Veterinary Journal, prevalence of atopic dermatitis in cats was reported to be over 12.5% in feline. As atopy causes distress, fur loss, and discomfort in cats, the need for feline atopic dermatitis treatment is expected to burgeon over the forecast period.
To curb the rising incidence of atopy in cats, professionals are using steroids and antibiotics to reduce the itchiness and fur loss. As steroids are cost-effective and effective, the corticosteroids segment is expected to gain traction, as per Future Market Insights (FMI).
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
One of the primary factors driving the growth in the market is rising adoption of companion animals such as dogs and cats across the globe. According to the National Kitten Coalition statistics, around 1.3 million cats are adopted every year as pets across the globe.
With rising adoption of cats, prevalence of skin allergies and other diseases in feline will improve the demand for feline atopic dermatitis treatments. Besides this, increasing number of veterinarians in developed regions such as North America and Europe will further spur the growth in the market.
With increasing number of pet adoption across the globe, prevalence of several animal diseases is also surging. Every year over 7.6 million companion animals such as cats and dogs enter shelter across the globe. Among which, over 3.4 million felines are adopted, as per the National Kitten Coalition.
However, lack of novel treatment in emerging economies such as Brazil, Argentina, India, and others might limit the growth in the market. Due to the lack of treatment, the chance of reoccurrence of atopic dermatitis is high. This might hamper the feline atopic dermatitis treatment market.
Another factor hampering the demand in the market is treatment cost of feline atopic dermatitis treatment. As per the study, the cost of this treatment is generally high, which might affect the sales in Latin America and Middle East & Africa.
Additionally, long-term side-effects of corticosteroids might limit the sales of oral treatment. This is expected to hinder the growth in the market.
Principal Consultant
Asia Pacific feline atopic dermatitis treatment market is anticipated to witness modest growth between 2022 and 2032, opines Future Market Insights (FMI). Asia Pacific is considered to be the emerging feline atopic dermatitis market owing to the rising pet ownership of cats and dogs in India, China, and Japan.
As per FMI, India is expected to spearhead the growth in Asia Pacific market over the forecast period. This is due to the increasing number of veterinarians in the country coupled with rising adoption of cats. Moreover, rise in the number of research organizations to develop novel medicines and treatment procedures in China will boost the market.
Further, greater penetration of leading players in India and adequate availability of treatment for pet animals will improve the demand in Asia Pacific market over the upcoming decade.
As per FMI, the U.S. is expected to account for significant share in North America feline atopic dermatitis treatment market. Around 1.9 million pets were adopted in 2020 across the U.S., according to the Pet Adoption Statistics. Out of which, there were 1.1 million cats and the number is projected to increase over the coming decade.
With growth in the number of pet adoption, prevalence of skin treatment among feline is also surging. This is expected to create lucrative growth opportunities for feline atopic dermatitis treatment market in North America.
Further, availability of reimbursement policies, growing number of veterinarians, and early adoption of novel medication and treatment in the U.S. will propel the demand in the North America market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Some of the leading manufacturers of feline atopic dermatitis treatment include Bayer AG, Pfizer Inc., Boehringer Ingelheim International GmbH Novartis AG, Eli Lily Company, Sanofi, Bristol-Myers Squibb Company, and Bausch Health Companies Inc. among others.
Key players in the feline atopic dermatitis treatment market are relying on merges and collaborative agreements to increase their revenue. They are also investing in research and development activities to develop novel treatments and medicines to expand their product portfolio.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 4.5% from 2022 to 2032 |
| Estimated Market Size (2022) | ~US$ 5 billion |
| Projected Market Size (2032) | ~US$ 7 billion |
| Base Year for Estimation | 2021 |
| Historical Data | 2015-2021 |
| Forecast Period | 2022-2032 |
| Quantitative Units | Revenue in US$ Million and CAGR from 2022-2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
As per FMI, the global feline atopic dermatitis treatment market demand is slated to increase at 4.5% CAGR during the forecast period.
North America is anticipated to dominate the global feline atopic dermatitis treatment market over the forecast period (2022-2032).
Overall demand in the feline atopic dermatitis treatment market is expected to exceed US$ 5 Bn by the end of 2022.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
3.5.1. Profit Margin Analysis
3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
3.7.1. By Key Regions
3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Drug Class, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Class, 2022-2032
5.3.1. Corticosteroids
5.3.2. Antihistamines
5.3.3. Antibiotics
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017-2021
5.5. Absolute $ Opportunity Analysis By Drug Class, 2022-2032
6. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Route of Administration, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032
6.3.1. Oral
6.3.2. Topical
6.3.3. Injectable
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2017-2021
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2022-2032
7. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By Distribution Channel, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
7.3.1. Veterinary Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017-2021
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2022-2032
8. Global Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Route of Administration
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Mexico
10.2.1.2. Brazil
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Route of Administration
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. U.K.
11.2.1.5. Spain
11.2.1.6. BENELUX
11.2.1.7. Russia
11.2.1.8. Rest of Europe
11.2.2. By Drug Class
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Route of Administration
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. East Asia Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Drug Class
12.2.3. By Route of Administration
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Route of Administration
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. South Asia & Pacific Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. ASEAN
13.2.1.3. Australia and New Zealand
13.2.1.4. Rest of South Asia & Pacific
13.2.2. By Drug Class
13.2.3. By Route of Administration
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Route of Administration
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. MEA Feline Atopic Dermatitis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Turkey
14.2.1.3. South Africa
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Route of Administration
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Route of Administration
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Feline Atopic Dermatitis Treatment Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Drug Class
15.1.2.2. By Route of Administration
15.1.2.3. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Drug Class
15.2.2.2. By Route of Administration
15.2.2.3. By Distribution Channel
15.3. Mexico
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Drug Class
15.3.2.2. By Route of Administration
15.3.2.3. By Distribution Channel
15.4. Brazil
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Drug Class
15.4.2.2. By Route of Administration
15.4.2.3. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Drug Class
15.5.2.2. By Route of Administration
15.5.2.3. By Distribution Channel
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Drug Class
15.6.2.2. By Route of Administration
15.6.2.3. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Drug Class
15.7.2.2. By Route of Administration
15.7.2.3. By Distribution Channel
15.8. U.K.
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Drug Class
15.8.2.2. By Route of Administration
15.8.2.3. By Distribution Channel
15.9. Spain
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Drug Class
15.9.2.2. By Route of Administration
15.9.2.3. By Distribution Channel
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Drug Class
15.10.2.2. By Route of Administration
15.10.2.3. By Distribution Channel
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Drug Class
15.11.2.2. By Route of Administration
15.11.2.3. By Distribution Channel
15.12. China
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Drug Class
15.12.2.2. By Route of Administration
15.12.2.3. By Distribution Channel
15.13. Japan
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Drug Class
15.13.2.2. By Route of Administration
15.13.2.3. By Distribution Channel
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Drug Class
15.14.2.2. By Route of Administration
15.14.2.3. By Distribution Channel
15.15. India
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Drug Class
15.15.2.2. By Route of Administration
15.15.2.3. By Distribution Channel
15.16. ASEAN
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Drug Class
15.16.2.2. By Route of Administration
15.16.2.3. By Distribution Channel
15.17. Australia and New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Drug Class
15.17.2.2. By Route of Administration
15.17.2.3. By Distribution Channel
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Drug Class
15.18.2.2. By Route of Administration
15.18.2.3. By Distribution Channel
15.19. Turkey
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Drug Class
15.19.2.2. By Route of Administration
15.19.2.3. By Distribution Channel
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Drug Class
15.20.2.2. By Route of Administration
15.20.2.3. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Route of Administration
16.3.4. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Bausch Health Companies Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Bayer AG
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. Pfizer Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. Novartis AG
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Eli Lily Company
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Sanofi
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Bristol-Myers Squibb Company
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Boehringer Ingelheim International GmbH
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Feline Atopic Dermatitis Treatment Market
